Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | kinase insert domain receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Onchocerca volvulus | Tyrosine kinase homolog | Get druggable targets OG5_130320 | All targets in OG5_130320 |
Loa Loa (eye worm) | TK/KIN16 protein kinase | Get druggable targets OG5_130320 | All targets in OG5_130320 |
Onchocerca volvulus | Get druggable targets OG5_130320 | All targets in OG5_130320 | |
Brugia malayi | Immunoglobulin I-set domain containing protein | Get druggable targets OG5_130320 | All targets in OG5_130320 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | defective proboscis extension response (dpr)-related | 0.0011 | 0.0032 | 0.0037 |
Echinococcus granulosus | neurotracting:lsamp:neurotrimin:obcam | 0.0015 | 0.0063 | 0.0032 |
Mycobacterium ulcerans | alpha-L-fucosidase | 0.1172 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0015 | 0.0063 | 0.0037 |
Trichomonas vaginalis | alpha-L-fucosidase, putative | 0.0442 | 0.373 | 0.5 |
Schistosoma mansoni | nephrin | 0.0014 | 0.0056 | 0.0066 |
Schistosoma mansoni | Neurotrimin precursor (hNT) | 0.0011 | 0.0032 | 0.0037 |
Echinococcus multilocularis | fucosidase, alpha L 1, tissue | 0.1172 | 1 | 1 |
Echinococcus multilocularis | neuroglian | 0.0014 | 0.0056 | 0.0025 |
Echinococcus granulosus | roundabout 2 | 0.0018 | 0.0088 | 0.0056 |
Loa Loa (eye worm) | alpha-L-fucosidase | 0.1008 | 0.8586 | 1 |
Trichomonas vaginalis | alpha-L-fucosidase, putative | 0.0442 | 0.373 | 0.5 |
Brugia malayi | Alpha-L-fucosidase family protein | 0.1008 | 0.8586 | 1 |
Echinococcus granulosus | neuroglian | 0.0014 | 0.0056 | 0.0025 |
Loa Loa (eye worm) | hypothetical protein | 0.0018 | 0.0088 | 0.0066 |
Loa Loa (eye worm) | TK/KIN16 protein kinase | 0.0183 | 0.1503 | 0.172 |
Echinococcus granulosus | twitchin | 0.0014 | 0.0056 | 0.0025 |
Schistosoma mansoni | vesicular amine transporter | 0.0011 | 0.0032 | 0.0037 |
Brugia malayi | Immunoglobulin I-set domain containing protein | 0.0183 | 0.1503 | 0.172 |
Onchocerca volvulus | Tyrosine kinase homolog | 0.0171 | 0.1399 | 1 |
Echinococcus multilocularis | roundabout 2 | 0.0018 | 0.0088 | 0.0056 |
Schistosoma mansoni | cell adhesion molecule | 0.0015 | 0.0063 | 0.0073 |
Schistosoma mansoni | alpha-l-fucosidase | 0.1008 | 0.8586 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0018 | 0.0088 | 0.0066 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | > 10 uM | Growth inhibition of human A431 cells overexpressing EGFR after 72 hrs by MTT assay | ChEMBL. | 17983745 |
GI50 (functional) | > 10 uM | Growth inhibition of human A431 cells overexpressing EGFR after 72 hrs by MTT assay | ChEMBL. | 17983745 |
IC50 (binding) | = 0.65 uM | Inhibition of KDR (unknown origin) | ChEMBL. | 17983745 |
IC50 (binding) | = 0.65 uM | Inhibition of KDR (unknown origin) | ChEMBL. | 17983745 |
Inhibition (binding) | = 7 % | Inhibition of HER2 (unknown origin) at 1 uM | ChEMBL. | 17983745 |
Inhibition (binding) | = 7 % | Inhibition of HER2 (unknown origin) at 1 uM | ChEMBL. | 17983745 |
Inhibition (binding) | = 36 % | Inhibition of Flt1 (unknown origin) at 1 uM | ChEMBL. | 17983745 |
Inhibition (binding) | = 36 % | Inhibition of Flt1 (unknown origin) at 1 uM | ChEMBL. | 17983745 |
Inhibition (binding) | = 65 % | Inhibition of EGFR (unknown origin) at 1 uM | ChEMBL. | 17983745 |
Inhibition (binding) | = 65 % | Inhibition of EGFR (unknown origin) at 1 uM | ChEMBL. | 17983745 |
Inhibition (binding) | = 73 % | Inhibition of KDR (unknown origin) at 1 uM | ChEMBL. | 17983745 |
Inhibition (binding) | = 73 % | Inhibition of KDR (unknown origin) at 1 uM | ChEMBL. | 17983745 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.